The treatment for CNS disease represents a growing and expanding segment of global drug development. The rise in prevalence of diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and anxiety and depression continues to drive demand for treatments. The growing burden highlights a significant unmet clinical need across the landscape.

At the recent CNS Forum in Shanghai, IQVIA experts shared the latest strategies and research trends driving innovation in the CNS space. This brief highlights advances in antipsychotics, clinical trial design, and patient-centric approaches in China. Learn how multidisciplinary collaboration and real-world evidence are shaping new solutions for unmet needs in this landscape.